Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5)	4/17/2014 10:20:39 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 136

>> confirms that the CSL anti-CD123 licensed by Janssen derives from a xncr license << Link, as usual, from Andy Biotech...... nature.com Targeting of acute myeloid leukemia in vitro and in vivo with an anti-cd123 mab engineered for optimal ADCC

To: scaram(o)uche who wrote (5)	9/29/2015 12:31:56 PM
From: scaram(o)uche	Respond to of 136

>> anti-CD123 << Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain MONROVIA, Calif., Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that its partner CSL Limited has initiated, through its licensee Janssen Biotech Inc., a Phase 2 clinical trial for CSL362 (now called JNJ-56022473), which uses Xencor's XmAb® Cytotoxic Fc Domain. "CSL's program is the third drug candidate using our XmAb technology to start Phase 2 clinical trials," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "By selectively licensing our XmAb technology, we believe we create value in non-core areas, thus allowing us to focus on advancing our key internal development programs." Xencor will receive an undisclosed milestone payment for the initiation of Phase 2 testing. Under the terms of the agreement signed in February 2009, Xencor granted CSL Limited a non-exclusive license to Xencor Cytotoxic Fc Domains for use in CSL programs, including CSL362. Xencor is also eligible to receive additional milestone payments and royalties on sales. In 2013, CSL Limited licensed CSL362 to Janssen Biotech Inc. (snip)